Developed by over 40 international experts, this set of practical guidelines is useful to in vitro diagnostic (IVD) innovators, clinical laboratories, regulatory scientists, and laboratory inspectors.
Browsing: Charles River
In these three posters, Charles Rivers (MA, USA) discuss the challenges associated with flow cytometry validation, compare data generated against that by microscopy, and compile historical immunophenotyping data in preclinical species.
In this manuscript, the European Bioanalysis Forum presents additional practice guidance on the use of flow cytometry in the support of drug development programs and addresses areas that are not covered in the previous publications.
In this interview, David Harris (Charles River Laboratories; NC, USA) discusses the current global landscape for cell therapy, associated safety concerns and challenges, and preclinical animal models that are used to evaluate cellular therapies.
Discover more about how Charles River (MA, USA) employs flow cytometry to support mouse model development in this interview with Christoph Eberle and Stephen Festin.
The 2019 Bioanalysis Rising Star Award finalists have been announced! Meet Sebastien Boridy (Charles River Laboratories, Montreal, Canada) your 2019 BRSA finalist.
Charles River Laboratories have signed an agreement to acquire Citoxlab for $510 million in a deal that aims to expand their global scale and scientific service portfolio.
In this feature, we will be investigating how flow cytometry works, key advances in technology over the years and how applications for flow cytometry detection and measurement are being developed.
We talk to Christoph Eberle, Principal Scientist at Charles River Laboratories (MA, USA). Christoph explains his fascination with flow cytometry, key advantages of the technique and where he hopes the field with be in 5–10 years’ time.